Toniv,

Just to clarify Don actually said that they would start to see results in a couple of months, not that all results would be available. Although it has been since December 2016 that we've had a corporate update webcast, the slides from Bio International from a few weeks ago had some new info. 

For the single agent ZEN-3694 study, they have initiated the recommended Phase 2 dose expansion cohort. The longest patient on drug now beyond 11 months. And they showed an MRI image example of stable mediastinalnodes over past 10 months from one of the patients. 

For the ZEN-3694/enzalutamide combo trial, the dose escalation is progressing. They are seeing dose proportional exposure. They have achieved target modulation shown at well tolerated doses. And the combo of ZEN-3694 and enzalutamide seems to be well tolerated.

I agree that we are long overdue a more comprehensive update, but I just wanted to point out the info that you may have missed.

 BearDownAZ

Toniv wrote: "On Dec 15th, 2016 Zenith provided a corporate update.

When Don talked about the zen3694 trial he said we see results in a couple of months. It is now 7 months down the road we have only seen one brief statement and as I recall there was nothing new in it.

This really has me wondering and beginning to have doubts. This trial is not blinded. There is no reason why we could not at least be informed of the status of the trial. Perhaps I missed it?

Frustrated. I wonder why they hired Mr Paradis and I am curious about what the IR people actually do all day. They certainly not occupied with communications that I can see. Perhaps it is all 1 on 1 dialogue with interested investors?

Toinv"